January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flywire Corporation (“Flywire” or “the Company”) (NASDAQ: FLYW). Investors who purchased Flywire securities prior to February 28, 2025, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST). Investors who purchased RxSight securities prior to November 7, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neogen Corporation (“Neogen” or “the Company”) (NASDAQ: NEOG). Investors who purchased Neogen securities prior to January 5, 2025, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings, Inc. (“Fortrea” or “the Company”) (NASDAQ: FTRE). Investors who purchased Fortrea securities prior to July 3, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Digimarc Corporation (“Digimarc” or “the Company”) (NASDAQ: DMRC). Investors who purchased Digimarc securities prior to May 3, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ibotta, Inc. (“Ibotta” or “the Company”) (NYSE: IBTA). Investors who purchased Ibotta securities prior to April 18, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Treace Medical Concepts, Inc. (“Treace Medical” or “the Company”) (NASDAQ: TMCI). Investors who purchased Treace Medical securities prior to May 8, 2023, and continue to hold to the present, are encouraged… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE). Investors who purchased Cerevel securities prior to October 11, 2023, and continue to hold to the present, are encouraged to obtain… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MGP Ingredients, Inc. (“MGP Ingredients” or “the Company”) (NASDAQ: MGPI). Investors who purchased MGP Ingredients securities prior to May 4, 2023, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ultra Clean Holdings, Inc. (“Ultra Clean” or “the Company”) (NASDAQ: UCTT). Investors who purchased Ultra Clean securities prior to May 6, 2024, and continue to hold to the present, are encouraged… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI). Investors who purchased Maravai securities prior to August 7, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Manhattan Associates, Inc. (“Manhattan Associates” or “the Company”) (NASDAQ: MANH). Investors who purchased Manhattan Associates securities prior to October 22, 2024, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ModivCare, Inc. (“ModivCare” or “the Company”) (NASDAQ: MODV). Investors who purchased ModivCare securities prior to November 3, 2022, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integral Ad Science Holding Corp. (“IAS” or “the Company”) (NASDAQ: IAS). Investors who purchased IAS securities prior to March 2, 2023, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arconic Corporation (“Arconic” or “the Company”) (NYSE: ARNC). Investors who purchased Arconic securities prior to April 19, 2022, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nextracker Inc. (“Nextracker” or “the Company”) (NASDAQ: NXT). Investors who purchased Nextracker securities prior to February 1, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Methode Electronics, Inc. (“Methode Electronics” or “the Company”) (NYSE: MEI). Investors who purchased Methode Electronics securities prior to December 2, 2021, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globe Life Inc. (“Globe Life” or “the Company”) (NYSE: GL). Investors who purchased Globe Life securities prior to May 8, 2019, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sharecare Inc. (“Sharecare” or “the Company”) (NASDAQ: SHCR). Investors who purchased Sharecare securities prior to May 10, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Innodata Inc. (“Innodata” or “the Company”) (NASDAQ: INOD). Investors who purchased Innodata securities prior to May 9, 2019, and continue to hold to the present, are encouraged to obtain additional information… read more
December 31, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ETHZilla Corporation (“ETHZilla” or “the Company”) (NASDAQ: ETHZ). Investors who purchased ETHZilla securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether ETHZilla has violated federal… read more
December 31, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bgin Blockchain Limited (“Bgin” or “the Company”) (NASDAQ: BGIN). Investors who purchased Bgin securities are encouraged to obtain additional information and assist the investigation. The investigation focuses on alleged violations of… read more
December 30, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Duluth Holdings Inc. (“Duluth” or “the Company”) (NASDAQ: DLTH). Investors who purchased Duluth securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Duluth has violated… read more
December 30, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Air Products and Chemicals, Inc. (“Air Products” or “the Company”) (NYSE: APD). Investors who purchased Air Products securities are encouraged to obtain additional information and assist the investigation. The investigation concerns… read more
December 30, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Air Products and Chemicals, Inc. (“Air Products” or “the Company”) (NYSE: APD). Investors who purchased Air Products securities are encouraged to obtain additional information and assist the investigation. The investigation concerns… read more
December 30, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Galectin Therapeutics Inc. (“Galectin” or “the Company”) (NASDAQ: GALT). Investors who purchased Galectin securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Galectin has violated… read more
December 23, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Above Food Ingredients, Inc. (“Above Food” or “the Company”) (NASDAQ: ABVE). Investors who purchased Above Food securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether… read more
December 22, 2025 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Insmed Incorporated (“Insmed” or “the Company”) (NASDAQ: INSM). Investors who purchased Insmed securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Insmed has violated federal… read more